Benchmark Downgrades Amedisys to Hold
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has downgraded Amedisys (NASDAQ:AMED) from Buy to Hold.
June 27, 2023 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amedisys has been downgraded from Buy to Hold by Benchmark analyst Bill Sutherland.
The downgrade from Buy to Hold by a Benchmark analyst indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100